In order to facilitate optimal detection and assessment of liver fibrosis and steatosis, the newly launched Hepatus 6 Diagnostic Ultrasound System offers the capabilities of real-time two-dimensional ultrasound with visual transient elastography in one device.
Offering a variety of automated tools and enhanced diagnostic functionality to aid in the diagnosis and quantification of liver fibrosis and steatosis, Minday has launched the Hepatus 6 Diagnostic Ultrasound System.
In addition to the benefits of two-dimensional (2D) and color Doppler imaging for the assessment of liver morphology, Mindray said the Hepatus 6 Diagnostic Ultrasound System provides access to visual transient elastography (ViTE) in the same device.
Automated features include quantitative analysis of liver stiffness, liver ultrasound attenuation analysis and one-click capture of 10 automated Q-scan measurements of fibrosis and steatosis within seconds, according to Mindray.
“The Hepatus 6 system provides clinicians a clear view of patient liver health and helps create a clear path forward for patients with chronic liver disease like no other system on the market today,” noted Wayne Quinn, the president of Mindray North America.
Mindray said another aspect of the Hepatus 6 Diagnostic Ultrasound System includes the ability to switch between the ViTE transducer and the curved ultrasound transducer to see greater real-time detail. The company added that an adjustable panel facilitates ergonomic workflow.
(Editor’s note: For related content, see “MRI Study Shows Higher Fibrosis Risk Among First-Degree Relatives of People with NAFLD and Advanced Fibrosis” and “Can Deep Learning Enhance Ultrasound Assessment of Hepatic Steatosis in Patients with NAFLD?”)
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
August 1st 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
August 1st 2025Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
August 1st 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.